%transitional cells (r2 ¼ 0.69, P < 0.0001) and plasmablasts (r2 ¼ 0.61, P < 0.0001) in RTX-N patients, but not in RTX-T patients. In RTX-N patients, BAFF levels and %BAFF-R þ B-cells were negatively correlated in total CD19 þ B-cells (r2 ¼ 0.49, P ¼ 0.0003), in naive B-cells (r2 ¼ 0.51, P ¼ 0.0002); and in post-switched B-cells (IgD-CD27þ) (r2 ¼ 0.5, P ¼ 0.0002). No such correlations were found after RTX. In RTX-N patients, there was a positive correlation between BAFF levels and total IgM and autoantibodies to dsDNA (r2 ¼ 0.53, 0.48, respectively; P < 0.005 for both) with median anti-dsDNA levels 908 IU (RTX-N) but not in RTX-T patients (median anti-dsDNA 558 IU). Conclusion: These results suggest that (IgDþ and IgD-) CD38þþ B-cells were differently sensitive to BAFF-mediated effects in RTX-N patients, compared with RTX-T patients. RTX treatment may therefore disrupt the aberrant interaction between BAFF and B-cells in RTX-N SLE patients. Serum anti-dsDNA antibodies and total IgM also correlated with BAFF levels in RTX-N patients but not in RTX-T. RTX treatment, may therefore remove pathogenic autoantibodies/immune complexes, which may be responsible for altering the functional consequences of both apparently disparate CD38þþ B cell subpopulations driven by BAFF.
Background: A high prevalence of foot problems causes reduced mobility and quality of life in patients with RA but it is not clear if this is important for patients with SLE. This study aimed to determine the frequency and clinical importance of forefoot inflammation in patients with SLE. Methods: A cross-sectional observational pilot study was performed in 20 consecutive patients with SLE. All participants met ACR criteria for SLE. Musculoskeletal ultrasound (US) was used to identify metatarsophalangeal joint (MTPJ) synovitis, flexor hallucis/digitorum longus (FHL/FDL) tenosynovitis and bursitis within the forefoot and the severity of each was graded from 0 to 3 according to the OMERACT system. Simultaneous US assessment of metacarpophalangeal joints (MCPJ) and flexor tenosynovitis within the hand was completed to allow comparison. Patients' self-reported foot impairment and activity limitation were assessed using the Foot Impact Scale questionnaire. Results: There were 18 females and 2 males; mean age 53.6 years. Overall disease activity was low with none of the patients having category A or B on the BILAG 2004 scoring system and mean SELENA-SLEDAI score of 0.35 AE 0.58 (0-2). All patients were taking disease modifying agents and 11 (55%) were receiving oral steroids. 70% had grade 1 synovitis or above in at least one MTPJ. 65% had grade 1 synovitis or above in at least one MCPJ. Those patients with MTPJ synovitis did not necessarily have MCPJ synovitis or vice versa. However, there was no significant difference in the prevalence of joint synovitis between the hands and feet (P ¼ 0.861). Forefoot tenosynovitis involving at least one site was seen in 25% of patients, whilst 5% had evidence of hand tenosynovitis. All patients had forefoot bursitis at one or more sites (with US evidence of hypertrophy and Doppler activity). Some level of foot-related impairment and activity limitation was registered by 95% and 85% of patients respectively. The mean score for self-reported foot impairment was 9.9 AE 5.3 (0-18) and footrelated activity limitation was 11.2 AE 9.7 (0-29). Reported foot impairment and activity limitation were not significantly associated with MTPJ synovitis (P ¼ 0.860 and P ¼ 0.325 respectively) or forefoot bursitis (P ¼ 0.243 and P ¼ 0.099 respectively). Forefoot bursitis was significantly associated with MCPJ synovitis (P ¼ 0.016) but not MTPJ synovitis (P ¼ 0.605). Conclusion: US detected inflammation within the forefeet of patients with SLE is common and potentially under-recognized clinically. This study suggests that patients with SLE report foot impairment and footrelated activity limitation comparable to that reported by patients with RA. Further research in this area is warranted. Funding: This work was supported by a grant from the Southampton Rheumatology Trust [SRT/2013/2 to S.M.] and L.C. was supported to undertake this work by a National Institute for Health Research Fellowship.
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PLACENTAL GROWTH FACTOR IS REDUCED IN LUPUS PATIENTS WITH ADVERSE PREGNANCY OUTCOMES
Christine Chew 1 , Ian Crocker 2 , Orsolya Kiss 2 , Alysha Allibone 2 , Clare Tower 2 and Ian N. Bruce 1 1 Arthritis Research Epidemiology Unit UK, University of Manchester, Manchester, 2 Faculty of Medical and Human Sciences, Maternal and Fetal Health Research Centre, University of Manchester, Manchester, UK Background: Women with SLE are at increased risk of poor obstetric and fetal outcomes. Currently, there are no valid biomarkers to aid the prediction of pregnancy-related complications. Maternal placental growth factor (PLGF) has been suggested as a marker of placental dysfunction, and a predictor of future early-onset pre-eclampsia, in otherwise low-risk primiparous women. We aimed to compare PLGF in women with SLE/lupus-like disease (SLE/LLD) with levels seen in healthy pregnant women and to determine how PLGF differed in SLE women in relation to subsequent pregnancy outcomes. Methods: SLE/LLD women (n ¼ 23) were recruited from our combined obstetrics-rheumatology clinic. Subjects were >18 years old with a diagnosis of SLE of LLD (i.e. !3 ACR criteria). Our healthy pregnant (NP) population (n ¼ 10) had no previous medical or obstetric complications. Twins and babies born with congenital abnormalities were excluded. Poor feto-maternal outcomes included: placental thickening, preterm labour, obstetric complications leading to miscarriage, intrauterine death or prematurity, low birth weight (n ¼ 5) and/ or admission to the special care baby unit. Arterial stiffness index (SI) was recorded by photoplethysmography. Serum PLGF was quantified by a rapid test kit. Results: We studied 23 SLE/LLD women and 10 healthy controls with a median (interquartile range: IQR) age of 33 (27-38) and 30.5 (28-37) years, respectively. Compared with healthy women with SLE/LLD had a trend towards lower, circulating PLGF (pg/ml) [median (IQR): 459.0 (131.0-975.0) vs 693.5 (502.0-963.0), respectively P ¼ 0.210]. SLE/LLD women with poor obstetric outcomes (n ¼ 9) had significantly reduced PLGF concentrations at 28 weeks gestation [median (IQR): 131.0 (67.7-424.0) vs 673.0 (419.0-978.0), P ¼ 0.032). PLGF levels did not correlate with mean arterial pressure, diastolic blood pressure or SI. Conclusion: In women with SLE and LLD, lower PLGF is associated with future pregnancy complications and may serve as a prognostic biomarker. Abnormal PLGF could reflect an imbalance of angiogenesis and increased systemic inflammation, and may contribute to impaired placental development or function in this population. PLGF assessments (!28 weeks gestation) may improve our ability to identify lupusaffected pregnancies requiring closer antenatal monitoring. Background: A significant amount of myocardial damage during a myocardial infarction (MI) occurs during the reperfusion stage, which is known as ischaemic reperfusion (I/R) injury and can account for up to 50% of cell death. SLE is a condition associated with a high burden of cardiovascular morbidity and mortality, when compared with the matched healthy population. Circulating autoantibodies such as antiphospholipid antibodies (aPL), which are found in 30-40% of SLE patients increase the risk of suffering an arterial thrombotic event. Studies performed by other groups have shown accelerated I/R injury in other systems such as mesenteric I/R injury in a lupus mouse model, however to date there has been no research focusing on the heart. The purpose of this study is to assess I/R injury in the presence of polyclonal IgG from patients with SLE AE aPL in an established in vitro model of simulated myocardial I/R injury utilizing neonatal rat cardiomyocytes.
Methods: Polyclonal IgG was isolated by protein G purification from serum of patients with SLE (n ¼ 23) and healthy controls (n ¼ 11) which were age and gender matched. Endotoxin was removed using Detoxi-Gel columns to a level below 0.225 endotoxin U/ml. We utilized an established in vitro model of anoxia/reoxygenation to I/R injury. Cardiomyocytes were isolated from 1-2 day old rat pups and when beating synchronously were treated with 500 mg/ml polyclonal IgG from each group and the following day exposed to simulated I/R injury using a hypoxic chamber (argon, 5% CO 2 ) followed by reoxygenation. Apoptosis was measured by assessment of caspase-3 cleavage using immunoblot and TUNEL. Results: In cells exposed to simulated I/R injury caspase-3 cleavage was not significantly increased in the presence of IgG from healthy volunteers (mean increase in caspase-3 cleavage of cells treated with healthy control IgG above untreated cells exposed to simulated I/R injury is 12.28% AE S.D. 26.01, n ¼ 10). However, in the presence of IgG from patients with SLE/aPL þve and SLE/aPL -ve, caspase-3 cleavage was increased above untreated cells exposed to simulated I/R injury by 58.74% (AES.D. 17.8, n ¼ 6) and 63.98 (AES.D. 17.9, n ¼ 8) and therefore significantly increased in comparison with healthy controls (P ¼ 0.0001). The effect observed with IgG from SLE patients was not altered when serum used in the buffers was heat inactivated suggesting a non-complement mediated mechanism. Conclusion: In this in vitro simulated I/R injury model IgG purified from patients with SLE significantly enhanced I/R injury as assessed by caspase-3 cleavage and TUNEL. This novel pathogenic role of these antibodies will now be tested in vivo to validate this finding and explore potential mechanisms of action. Disclosure statement: The authors have declared no conflicts of interest.
CHARACTERIZING A POPULATION WITH SEROLOGICAL FEATURES OF ANCA-ASSOCIATED VASCULITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS
Joanna M. Belcher 1 , Dylan J. Mac Lochlainn 1 , Aine Burns 2 , Ruth Yang 2 and Alan Salama 2 1 Faculty of Medical Sciences, University College London, London, 2 Department of Nephrology, Royal Free Hospital, London, UK Background: The role of anti-neutrophil cytoplasmic antibodies (ANCA) in the diagnosis and pathogenesis of overlap syndromes is a source of contention. Previous studies have indicated that although ANCA-Associated Vasculitis (AAV) and SLE are autoimmune conditions that most commonly exist independently of one another, their respective immunological markers, those of ANCA and anti-dsDNA, may co-exist. Double positivity (ANCA and anti-dsDNA positive) is thought to be of importance as it may cause an atypical presentation of either condition or an increased severity of clinical manifestation. This effect is of particular importance with respect to renal function, as both diagnoses may result in renal disease. However, this area requires further investigation as existing literature is sparse. Therefore, our objectives were to define the clinical, serological, and pathological features of a patient population with anti-dsDNA and ANCA, with particular emphasis on the extent of renal disease in this group. Methods: An immunology database search was conducted for patients who had a positive test for anti-dsDNA and ANCA (with either anti-MPO or anti-PR3 antibodies by ELISA) between 2005 and 2013. The clinical features of these patients were subsequently examined in detail, with a particular focus on SLE and AAV histological manifestations. Results: A cohort of 27 patients was identified, from which 7 patients were excluded: 4 due to conditions associated with polyclonal B-cell responses (lymphoma, HIV infection, and drug-induced lupus) and 3 due to insufficient data. Of the remaining 20 patients, 10 had clinical SLE, 5 had clinical AAV, 2 had mixed connective-tissue disease/ scleroderma, and 3 were unclassified. In the double positive SLE patients, the time from diagnosis to end-stage renal failure (ESRF) was found to be significantly shorter (P < 0.0001) than the control group (consisting of a contemporaneous clinic population of anti-dsDNA positive, ANCA negative SLE patients), suggesting ANCA positivity augmented kidney injury. A comparison of the AAV cohort with a control group was not conducted due to fewer double positive AAV patients. Although the majority of patients had clinical and pathological features consistent with either SLE or AAV, one patient had histological features of both, demonstrating a true clinical overlap of these conditions. Conclusion: SLE is the most common clinical and pathological diagnosis associated with anti-dsDNA and ANCA positivity. ANCA positivity in these patients correlated with a more rapid progression to ESRF. Although patients with AAV may also be anti-dsDNA positive, the consequence of this double positivity remains to be determined. All patients with SLE or AAV should have a complete autoantibody profile examined to better define the importance of this double positive population. Disclosure statement: The authors have declared no conflicts of interest.
